Nitazoxanide
It is a commercial antiprotozoal agent with an antiviral capacity against a wide range of viruses, including human and animal coronaviruses, reported to be resistance to 2019-nCoV, at low micromolar concentrations, such as - EC50 = 2.12 μM; CC50 > 35.53 μM; SI > 16.76 [10]. Further in vivo evaluation of this medication is suggested against 2019-nCoV infection. Authorized for diarrhea therapy, Neitazoxanide has the potentiality to inhibit 2019-nCoV and thus, needs clinical trials to determine the antiviral efficacy of this drug [12] [15].